Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • NatashaPavlovikj
    Junior Member
    • Feb 2013
    • 8

    Create longer contigs from transcriptome assembly

    Hi everyone,

    I am doing transcriptome assembly on short Illumina reads (both single end and paired end with avg length of 100 bp).
    I use different transcriptome assemblers, like MIRA, Velvet Oases, SOAPdenovoTrans.
    The avg contig length I got varies from 400 to 1000 bp.
    I tried different parameters, like different kmer and different min contig size, but the result does not improve a lot.
    I am interested in making much longer contigs (few thousands), so I was wondering is there any way how can I improve and increase this current contig length.
    Also, I would like to know why this length varies a lot between different transcriptome assemblers (there is a huge difference between length 400 and length 1000).
    I know that Velvet and SOAPdenovo are based on de Bruijn graphs, while MIRA is OLC based.

    I would appreciate a lot if someone can share some similar experience with me.
    Thank you very much,
    Best Regards,
    Natasha
  • westerman
    Rick Westerman
    • Jun 2008
    • 1104

    #2
    So ... what average contig length do you expect? And why? While the transcriptome projects that come through my hands do generate some transcripts in the 'few thousands' most of them are much shorter.

    The average length *may* vary because of the number of short transcripts being kept between the various programs. If one program keeps all transcripts while another throws away transcripts less than 200 bases then your average will vary even if the longest transcripts do not. Really you can not say much about average lengths unless you also know the shortest/longest lengths and the distribution.

    Comment

    • westerman
      Rick Westerman
      • Jun 2008
      • 1104

      #3
      Also, if you are going to do denovo transcriptome assembly then you really owe it to yourself to try out Trinity instead of using non-transcriptome assemblers.

      Comment

      • Wallysb01
        Senior Member
        • Feb 2011
        • 286

        #4
        The length of your assemblies will be greatly impacted on expression level of the genes you're assembling. Even in very deeply sequenced samples, and with replicates, its going to be very hard to assemble very many genes from TSS to polyA, or even start to stop codon. Simple statistics like N50, or mean length, just don't mean much for transcriptomes.

        You need to do some sort of orthology assignment to get an idea of how complete your assembly is, or how one assembly compares to another. If you're going for simple statistics about your assembly. I'd much rather just look at number of transcripts >1kbp than N50/average length, because its usually in the 500-1000bp range that you start getting meaningful information for downstream analysis.

        And to try to answer your questions about how to improve assembly length, I would just say try trans-ABySS (which uses multiple k-mer approach and might be the best assembler in terms of completeness) and Trinity (does a nice job with length and ease of downstream analysis). From your use of Velvet Oases, it sounds like you're doing this on microbes, but you may still find success with those two.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        18 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-23-2026, 11:41 AM
        0 responses
        18 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-20-2026, 11:10 AM
        0 responses
        25 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-13-2026, 10:26 AM
        0 responses
        37 views
        0 reactions
        Last Post SEQadmin2  
        Working...